Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies.

Abstract

The poor translational validity of autoimmune-mediated inflammatory disease (AIMID) models in inbred and specific pathogen-free (SPF) rodents underlies the high attrition of new treatments for the corresponding human disease. Experimental autoimmune encephalomyelitis (EAE) is a frequently used preclinical AIMID model. We discuss here how crucial information needed for the innovation of current preclinical models can be obtained from postclinical analysis of the nonhuman primate EAE model, highlighting the mechanistic reasons why some therapies fail and others succeed. These new insights can also help identify new targets for treatment.

DOI: 10.1016/j.drudis.2014.03.023

3 Figures and Tables

Cite this paper

@article{Hart2014ImprovementOP, title={Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies.}, author={Bert A 't Hart and S Anwar Jagessar and Yolanda S. Kap and Krista G Haanstra and Ingrid H. C. H. M. Philippens and Ch{\'e} Serguera and Jan A. M. Langermans and Michel P. M. Vierboom}, journal={Drug discovery today}, year={2014}, volume={19 9}, pages={1394-401} }